SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Profiteer who wrote (1641)6/24/1998 1:27:00 AM
From: chirodoc   of 5402
 
HERE IS WHERE IT ALL BEGAN..JAPAN

......Using the oxygen-carrying, so-called "artificial blood", Fluosol-DA, "developed by us"

........ The operation was performed "quite safely" despite a large blood loss, a stable condition was performed quite safely despite a large blood loss, a stable condition being maintained during and after the operation.

Int Surg 1981 Oct;66(4):355-358

Success in the radical resection of esophageal cancer with artificial blood infusion: case report.

Mitsuno T, Kawa Y, Kita A, Kohno N

Using the oxygen-carrying, so-called "artificial blood", Fluosol-DA, developed by us, we successfully performed a radical resection for esophageal cancer and a one-stage reconstruction, without any blood transfusion. The operation was performed quite safely despite a large blood loss, a stable condition was performed quite safely despite a large blood loss, a stable condition being maintained during and after the operation. Fluosol-DA has no relation to blood type and is stable in a frozen state for one year or more and can, therefore, be used conveniently and safely for treating severe and intraoperative hemorrhages. Furthermore, this preparation may well have at wide application because it greatly reduces the risk of postoperative hepatitis.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext